What's Behind The Jump In Hims & Hers Health Stock?

Shares of Hims & Hers Health, Inc. (NASDAQ:HIMS) are rising Monday after Secretary of Health and Human Services Robert F. Kennedy Jr. said on the Joe Rogan podcast that several peptide compounds, a popular wellness treatment, would be added to an approval list.

• Hims & Hers Health stock is surging to new heights today. What’s driving HIMS stock higher?

14 Peptides To Be Moved From Category 2 List

Kennedy announced on the Joe Rogan Experience podcast over the weekend that 14 peptides that were previously placed on the FDA's Category 2 list would be moved back to Category 1. The Category 2 list classifies the peptides as "do not compound."

The move could allow U.S.-based compounding pharmacies, like the organizations that Hims & Hers relies on, to make the peptides without risk of being shut down. Hims & Hers bought a peptide facility in California last year, poising the company to take advantage of the new categorization.

According to the podcast, many consumers currently purchase peptides online from a “grey market.” Kennedy’s move to approve the peptides would allow Hims & Hers to take advantage of the consumer base currently buying off the grey market.

"The future of healthcare must be centered on the customer, which is why our operational structure is built to scale personalized care to more individuals at the highest standard of quality and safety, and with a focus on long-term consistency and availability," Melissa Baird, COO of Hims & Hers, said last year.

HIMS Shares Trade Higher

HIMS Price Action: Hims shares are up 7.58% at $15.62 at the time of publication on Monday. During today’s trading, the stock hit a high of $15.79 and a low of $14.31.

Hims & Hers Health, Inc. is currently trading significantly below its historical moving averages, indicating a bearish trend over the past year. The stock is 17.1% below its 20-day SMA and a stark 64.7% below its 200-day SMA. Over the last 12 months, the stock has decreased by 61.75%, and it is trading closer to its 52-week low of $13.74 than its high of $70.43.

The RSI stands at 15.87, signaling that the stock is in the oversold territory, which could suggest a potential for rebound or at least stabilization in the short term. Meanwhile, the MACD presents a bullish signal, with the MACD line at -3.7847 above the signal line at -3.9728, indicating a possible increase in upward momentum despite the overall downtrend.

Image: Shutterstock